Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...

ChemLex launches an AI-powered, robot-run lab in Singapore to accelerate drug discovery and development, reducing time and ...

Clinical trials for drug development are notoriously slow and expensive, and only a small fraction of drug candidates end up being approved by the regulatory authorities. The extensive bottlenecks in ...

Key opportunities in the Global API CDMO Market include expanding pharmaceutical R&D, rising demand for complex therapies, ...

Partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate to treat degenerative disorders of retina, with view to starting clinical trials in ...

Comprehensive coverage of Teva Pharmaceutical Industries, detailing global operations, research, specialty medicines, and ...

The antimalarial product development partnership (PDP), Medicines for Malaria Venture (MMV), has joined the Liverpool-based Infection Innovation Consortium: iiCON as a core partner. The non-profit ...

While many headline-grabbing biologics and advanced therapeutics like cell and gene therapies are approved as injectables, ...

ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million ...

AGC Biologics is set to expand its Cell Line Development Centre of Excellence through a partnership with ATUM.

Researchers at Martin Luther University Halle-Wittenberg (MLU) have developed a promising new substance for targeting ...

Researchers at Martin Luther University Halle-Wittenberg (MLU) have developed a promising new substance for targeting bacteria that cause tuberculosis. The team have produced a compound that inhibits ...